Study finds Bluesky and X users share clinical trial information differently, which could impact recruitment strategies ...

Monthly insights, guidance alerts and blogs from global life sciences law firms, compiled for you in one place.

The legal experts recently discussed the mechanics of direct-to-patient (DTP) and direct-to-employer (DTE) models.

Drug studies in Ontario, Canada, can now start in just 45 days through a study review pathway recently introduced by ...

The company has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 ...

Investor risk aversion was identified as the leading constraint on biotech investment, cited by 64% of respondents. In Europe ...

Prader-Willi syndrome is a rare genetic condition that can present from birth. Its occurrence is around 1 in 15,000, and tens ...

Viatris will acquire all outstanding shares of Pacira's common stock for $36.50 per share, representing an aggregate equity ...

BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending October 11, 2026.

Pharma industry is navigating its biggest drug pricing compliance overhaul since 2006, as CMS’ 2026 Physician Fee Schedule ...

This webinar will explore integrating the Pfenex Expression Technology® platform directly into the antibody screening ...

Partnership aims to improve patient access and adherence through mobile-first engagement platform for life sciences firms ...